Learning the chemical grammar of biomolecular condensates
Biomolecular condensates compartmentalize and regulate assemblies of biomolecules
engaged in vital physiological processes in cells. Specific proteins and nucleic acids …
engaged in vital physiological processes in cells. Specific proteins and nucleic acids …
Epigenetic mechanisms in breast cancer therapy and resistance
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …
pathway represent the main treatment modality. Endocrine therapy has proven successful in …
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
JO Brett, LM Spring, A Bardia, SA Wander - Breast Cancer Research, 2021 - Springer
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …
Therapeutic resistance to anti-oestrogen therapy in breast cancer
The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …
gland development, breast carcinogenesis and the progression of breast tumours into lethal …
Biomolecular condensates and cancer
Malignant transformation is characterized by dysregulation of diverse cellular processes that
have been the subject of detailed genetic, biochemical, and structural studies, but only …
have been the subject of detailed genetic, biochemical, and structural studies, but only …
Partitioning of cancer therapeutics in nuclear condensates
The nucleus contains diverse phase-separated condensates that compartmentalize and
concentrate biomolecules with distinct physicochemical properties. Here, we investigated …
concentrate biomolecules with distinct physicochemical properties. Here, we investigated …
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
B O'Leary, S Hrebien, JP Morden, M Beaney… - Nature …, 2018 - nature.com
CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with
advanced estrogen receptor-positive breast cancer, although there are no predictive …
advanced estrogen receptor-positive breast cancer, although there are no predictive …
GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast …
J Liang, JR Zbieg, RA Blake, JH Chang… - Journal of Medicinal …, 2021 - ACS Publications
Breast cancer remains a leading cause of cancer death in women, representing a significant
unmet medical need. Here, we disclose our discovery efforts culminating in a clinical …
unmet medical need. Here, we disclose our discovery efforts culminating in a clinical …
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer …
MR Lloyd, SA Wander, E Hamilton… - Therapeutic …, 2022 - journals.sagepub.com
Endocrine therapy (ET) is a pivotal strategy to manage early-and advanced-stage estrogen
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
W Toy, H Weir, P Razavi, M Lawson, AU Goeppert… - Cancer discovery, 2017 - AACR
Recent studies have identified somatic ESR1 mutations in patients with metastatic breast
cancer and found some of them to promote estrogen-independent activation of the receptor …
cancer and found some of them to promote estrogen-independent activation of the receptor …